| Bioactivity | TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells[1]. |
| CAS | 364621-46-5 |
| Formula | C15H13BrN2OS |
| Molar Mass | 349.25 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qiu D, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024 Sep 12;13(1):33. |
TFCP2L1-IN-1
CAS: 364621-46-5 F: C15H13BrN2OS W: 349.25
TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 syn
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.